X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PIRAMAL ENTERPRISES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PIRAMAL ENTERPRISES NOVARTIS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 392.3 9.4 4,176.2% View Chart
P/BV x 31.4 1.7 1,829.8% View Chart
Dividend Yield % 1.5 1.0 153.2%  

Financials

 NOVARTIS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NOVARTIS
Mar-18
PIRAMAL ENTERPRISES
Mar-18
NOVARTIS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs7583,083 24.6%   
Low Rs5791,902 30.4%   
Sales per share (Unadj.) Rs228.4589.7 38.7%  
Earnings per share (Unadj.) Rs31.7284.0 11.2%  
Cash flow per share (Unadj.) Rs32.8310.5 10.6%  
Dividends per share (Unadj.) Rs10.0025.00 40.0%  
Dividend yield (eoy) %1.51.0 149.1%  
Book value per share (Unadj.) Rs297.11,467.0 20.3%  
Shares outstanding (eoy) m24.69180.27 13.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.94.2 69.3%   
Avg P/E ratio x21.18.8 240.0%  
P/CF ratio (eoy) x20.48.0 254.2%  
Price / Book Value ratio x2.21.7 132.4%  
Dividend payout %31.58.8 358.0%   
Avg Mkt Cap Rs m16,505449,332 3.7%   
No. of employees `0000.76.8 9.8%   
Total wages/salary Rs m1,44519,881 7.3%   
Avg. sales/employee Rs Th8,441.315,535.6 54.3%   
Avg. wages/employee Rs Th2,163.62,905.4 74.5%   
Avg. net profit/employee Rs Th1,173.17,482.5 15.7%   
INCOME DATA
Net Sales Rs m5,639106,310 5.3%  
Other income Rs m1,7182,595 66.2%   
Total revenues Rs m7,357108,906 6.8%   
Gross profit Rs m-6351,599 -0.1%  
Depreciation Rs m254,773 0.5%   
Interest Rs m5529,783 0.2%   
Profit before tax Rs m1,57519,638 8.0%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792-28,764 -2.8%   
Profit after tax Rs m78451,203 1.5%  
Gross profit margin %-1.148.5 -2.3%  
Effective tax rate %50.3-146.5 -34.3%   
Net profit margin %13.948.2 28.9%  
BALANCE SHEET DATA
Current assets Rs m9,522118,154 8.1%   
Current liabilities Rs m3,296462,260 0.7%   
Net working cap to sales %110.4-323.7 -34.1%  
Current ratio x2.90.3 1,130.2%  
Inventory Days Days3727 137.8%  
Debtors Days Days2847 61.1%  
Net fixed assets Rs m46113,727 0.0%   
Share capital Rs m123361 34.2%   
"Free" reserves Rs m7,213264,093 2.7%   
Net worth Rs m7,336264,454 2.8%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m11,105726,834 1.5%  
Interest coverage x29.51.7 1,776.9%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.50.1 347.2%   
Return on assets %7.611.1 67.8%  
Return on equity %10.719.4 55.2%  
Return on capital %22.210.3 215.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6115,110 0.4%   
Fx outflow Rs m3,6304,298 84.5%   
Net fx Rs m-3,57010,813 -33.0%   
CASH FLOW
From Operations Rs m1,610-159,666 -1.0%  
From Investments Rs m687-17,677 -3.9%  
From Financial Activity Rs m-2,677186,503 -1.4%  
Net Cashflow Rs m-3809,364 -4.1%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.0 50.0%  
FIIs % 1.6 26.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 16.5 130.3%  
Shareholders   41,647 93,274 44.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Uptrend, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 18, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PFIZER COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS